Mar 27, 2017
License agreement with ADARC for Bispecific Antibodies technology
Bases on several years negotiation, The Aaron Diamond AIDS Research Center (ADARC) and TaiMed Biologics Inc.(TaiMed) finally agreed on March 27, 2017 to sign a world-wide, exclusive, non-transferable license under the ADARC Patent Rights to discover, develop, make, have made, use, import, lease, sell and offer for sale Licensed Products which its technology developed by Dr. David Ho under a grant from the Bill & Melinda Gates Foundation relating to “IMPROVED HIV-1-NEUTRALIZING ANTIBODY POTENCY AND BREADTH VIA CELL RECEPTOR ANCHORING USING BISPECIFIC ANTIBODIES WITH NATIVE ARCHITECTURE”.
The Bispecific Antibodies technology will be TaiMed third generation for HIV biologics pipelines (TMB-355 and TMB-365 will be the first and second generation pipelines, respectively). The license terms cannot be disclosure based on the mutual confidential agreement in the contract.
Source：TaiMed Biologics Inc.
http://www.taimedbiologics.com/news/info/57
The Bispecific Antibodies technology will be TaiMed third generation for HIV biologics pipelines (TMB-355 and TMB-365 will be the first and second generation pipelines, respectively). The license terms cannot be disclosure based on the mutual confidential agreement in the contract.
Source：TaiMed Biologics Inc.
http://www.taimedbiologics.com/news/info/57